US HAI Infections by State

Investigating Prevalence and Prevention of Healthcare-Associated Infections

By Health [source]

About this dataset

This dataset provides a comprehensive overview of Healthcare-Associated Infections (HAIs) across all US states. Spanning multiple subspecialty areas such as central lines and urinary catheters infections, HAIs can be devastating to patient care and outcomes. The data within this set is collected by the Centers for Disease Control and Prevention (CDC) through the National Healthcare Safety Network (NHSN). It contains information on infection rates along with other important data such as measure names, scores, footnotes and measure start & end dates. This dataset presents us with an opportunity to better understand the prevalence of HAIs on a state level in order to improve patient safety measures that are used in hospitals nationwide

More Datasets

For more datasets, click here.

Featured Notebooks

• 🚨 Your notebook can be here! 🚨!

How to use the dataset

This dataset provides valuable insights into healthcare-associated infections (HAIs) across the United States. By understanding which states have higher rates of HAIs, we can better understand the overall state of health care in the country.

To get started using this data set, take a look at some of the columns included: Measure Name, Score, Footnote and Measure Start and End Date. The measure name will give you an overview of what type of infection is being measured in each state. Each measurement has an associated score that tells you how well each state is doing with respect to other states when it comes to preventing these infections from occurring. The footnote gives more information about specific details surrounding that particular HAI measure for that state (for instance, if all or only some hospitals are included in the measure). Finally, the start and end dates tell you when the measure began and ended in regards to data collection for each state.

Once you have explored some of these columns, start looking deeper into what data points each column contains - such as which states have a high number of infections related to surgical procedures compared to others who don't? Thinking critically about this data will reveal trends amongst different states and how they compare when it comes to providing quality health care services within their facilities.

By exploring these trends further with visuals such as charts or graphs, you can better determine which areas need improvement so that we may develop preventative measures against further incidences occurring in hospitals across all US states

Research Ideas

• Creating a state-by-state map of healthcare-associated infection rates in order to identify which states have the highest and lowest rates of HAIs.
• Developing a predictive model to determine the likelihood of an infection in a particular hospital based on data from all the other hospitals in the same state, allowing hospitals to adjust their safety protocols accordingly.
• Constructing an infographic displaying different points picked up within this dataset such as what are common sources of infection, breakdowns by states and types, etc

Acknowledgements

If you use this dataset in your research, please credit the original authors. Data Source

License

License: Open Database License (ODbL) v1.0 - You are free to: - Share - copy and redistribute the material in any medium or format. - Adapt - remix, transform, and build upon the material for any purpose, even commercially. - You must: - Give appropriate credit - Provide a link to the license, and indicate if changes were made. - ShareAlike - You must distribute your contributions under the same license as the original. - Keep intact - all notices that refer to this license, including copyright notices. - No Derivatives - If you remix, transform, or build upon the material, you may not distribute the modified material. - No additional restrictions - You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.

Columns

File: Healthcare_Associated_Infections_-_State.csv | Column name | Description | |:-----------------------|:------------------------------------------------------------------------------------------------------------------------|...

According to Cognitive Market Research, the global Hospital-Acquired Infection Diagnostic market size is USD 29845.2 million in 2024. It will expand at a compound annual growth rate (CAGR) of 2.90% from 2024 to 2031.

North America held the major market share for more than 40% of the global revenue with a market size of USD 11938.08 million in 2024 and will grow at a compound annual growth rate (CAGR) of 1.1% from 2024 to 2031.
Europe accounted for a market share of over 30% of the global revenue with a market size of USD 8953.56 million.
Asia Pacific held a market share of around 23% of the global revenue with a market size of USD 6864.40 million in 2024 and will grow at a compound annual growth rate (CAGR) of 4.9% from 2024 to 2031.
Latin America had a market share of more than 5% of the global revenue with a market size of USD 1492.26 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.3% from 2024 to 2031.
Middle East and Africa had a market share of around 2% of the global revenue and was estimated at a market size of USD 596.90 million in 2024 and will grow at a compound annual growth rate (CAGR) of 2.6% from 2024 to 2031.
Hospital held the highest Hospital-Acquired Infection Diagnostic market revenue share in 2024.

Market Dynamics of Hospital-Acquired Infection Diagnostic Market

Key Drivers for Hospital-Acquired Infection Diagnostic Market

Growing Prevalence of HAIs to Increase the Demand Globally

The Hospital-Acquired Infections Diagnostics Market is primarily driven by the ongoing increase in HAIs worldwide. The growing prevalence of these diseases highlights how important it is to have efficient diagnostic tools to recognize and treat infections contracted when a patient is in a medical facility. In the United States, an HAI affects around 1 in every 31 hospitalized patients at any given moment, according to Centers for Disease Control and Prevention (CDC) research. This means that 633,300 individuals get an HAI each year. Every year, the healthcare system in the United States sees more than a million HAIs. Tens of thousands of people lose their lives as a result of these illnesses every year, which can cause serious morbidity and death. According to estimates, HAIs cost billions of dollars a year.

Source: https://psnet.ahrq.gov/primer/health-care-associated-infections.

Rising Collaboration to Propel Market Growth

The increasing collaboration among the key players is expected to propel the market growth over the projected period. For instance, in February 2023, Roche announced that it has strengthened its research and innovation efforts by expanding its partnership with Janssen Biotech Inc. (Janssen) to develop companion diagnostics for targeted treatments. With several companion diagnostics technologies, such as immunohistochemistry (IHC), digital pathology, next-generation sequencing, polymerase chain reaction, and immunoassays, Roche and Janssen now have more opportunities to work together in the precision medicine space thanks to the new, enlarged partnership.

Source: https://diagnostics.roche.com/global/en/news-listing/2023/roche-expands-collaboration-with-janssen-to-advance-personalised.html.

Restraint Factor for the Hospital-Acquired Infection Diagnostic Market

High Cost and Lack of Skilled Personnel to Limit the Sales

The cost of advanced diagnostic equipment and technologies may prevent them from being widely used, particularly in poor countries with tighter budgets and in smaller healthcare facilities. The entire cost of healthcare may also rise due to the high cost of reagents and equipment. Furthermore, the proficiency of medical practitioners influences the efficacy of diagnostic procedures. Market expansion may be hampered by a lack of qualified laboratory workers and medical professionals versed in the use of cutting-edge diagnostic equipment.

Impact of Covid-19 on the Hospital-Acquired Infection Diagnostic Market

The hospital-acquired infection (HAI) diagnostic market has been impacted by the COVID-19 pandemic in several ways. While there have been several difficulties, there have also been fresh prospects and developments in healthcare procedures that may ultimately be advantageous to the market. Due to the pandemic, financial investments, manpower, and equipment were reallocated to the COVID-19 management effort. This change took resources and focus away from other areas of healthcar...

This dataset includes central line-associated bloodstream infection (CLABSI) data reported by California hospitals to the California Department of Public Health (CDPH), Healthcare-Associated Infections (HAI) Program, via the Centers for Disease Control and Prevention (CDC) National Healthcare Safety Network (NHSN). Hospital types include acute care, critical access, long-term acute care, free-standing rehabilitation hospitals, as well as acute rehabilitation units that report data separately. CLABSI data for each hospital include the number of infections observed (reported) and predicted (based on national baseline data), the number of central line-days, the Standardized Infection Ratio (SIR) and associated 95% confidence intervals, and statistical interpretation to show whether CLABSI incidence was the same (no different), better (lower), or worse (higher) than the national baseline. Central line insertion practices (CLIP) adherence percent for each hospital is calculated from data reported by all critical care locations (i.e., critical care areas, neonatal critical care, and one special care area, "Oncology - Medical/Surgical Critical Care"). In 2021, the CLIP reporting requirement to CDPH via NHSN was discontinued. CLABSI SIRs are influenced by clinical and infection control practices related to central line insertion and infection control maintenance practices, patient-based risk factors, and surveillance and reporting methods. Health and Safety Code section 1288.55(a)(2) requires general acute care hospitals to report to CDPH all cases of CLABSI identified in their facilities. For general information about NHSN, surveillance definitions, and reporting requirements for CLABSI, please visit: https://www.cdc.gov/nhsn/index.html To link the CDPH facility IDs with those from other Departments, including OSHPD, please reference the "Licensed Facility Cross-Walk" Open Data table at: https://data.chhs.ca.gov/dataset/licensed-facility-crosswalk. For information about healthcare-associated infection prevention progress in California hospitals and statewide prevention goals, please visit: https://www.cdph.ca.gov/Programs/CHCQ/HAI/Pages/HAIreport.aspx

Overview

The Global Hospital Acquired Infection (HAI) Control Market is projected to reach USD 10.7 billion by 2032, up from USD 6.5 billion in 2022, at a CAGR of 5.1% during 2023–2033. The increasing prevalence of HAIs remains the most prominent driver. Infections such as bloodstream infections, urinary tract infections, pneumonia, and surgical site infections affect millions of patients annually. According to WHO, these infections are more frequent in developing economies. This rising burden has intensified demand for hospital infection prevention measures worldwide.

Regulatory policies and international guidelines have played a pivotal role in driving adoption. Healthcare authorities such as the CDC, ECDC, and WHO have mandated stricter infection prevention protocols. These frameworks require hospitals to implement sterilization, disinfection, and continuous surveillance systems. Compliance pressures have encouraged hospitals to invest in advanced products and services. Regulatory oversight has thereby created a significant growth opportunity for providers of infection control equipment, consumables, and digital monitoring solutions.

Technological advancements have also transformed infection control practices. Next-generation innovations such as UV-C disinfection devices, automated room sterilization systems, and antimicrobial surface coatings have strengthened hospital safety. Digital surveillance and AI-based infection monitoring tools are improving real-time tracking, thereby enhancing preparedness against HAIs. The integration of smart technologies has been observed to increase operational efficiency, reduce transmission risks, and align hospitals with evolving global safety standards. These advancements are expected to remain a major growth enabler.

Healthcare expenditure and infrastructure development further contribute to expansion. Investments in modern hospitals, intensive care units, and surgical facilities are rising globally, particularly in emerging markets. Post-pandemic healthcare strengthening has accelerated adoption of sterilization units, disinfectants, protective barriers, and infection monitoring systems. Government and private investments in healthcare facilities have ensured the demand for comprehensive infection control solutions. This structural improvement has positioned the sector for sustained growth, as countries seek long-term resilience in infection prevention.

Patient Demographics, Awareness, and Pandemic Impact

Growing awareness and training programs are also contributing to the hospital acquired infection control market. Initiatives promoting hand hygiene, sterilization protocols, and antimicrobial stewardship are gaining importance. Hospitals are increasingly adopting structured training and certification programs for healthcare staff. This rising awareness has resulted in higher demand for infection control supplies and technologies, as hospitals seek to minimize risks associated with patient safety and meet international healthcare quality standards. Awareness campaigns are expected to remain an integral part of market growth strategies.

The aging population and the rising number of high-risk patient groups also drive demand. Elderly individuals and patients with chronic diseases such as cancer, diabetes, and cardiovascular conditions are more vulnerable to hospital infections. This demographic shift is creating sustained demand for infection prevention across hospitals, rehabilitation centers, and long-term care facilities. As the global geriatric population grows, healthcare systems are increasingly required to enhance infection control practices, ensuring greater safety for these high-risk groups.

The COVID-19 pandemic acted as a major catalyst in reshaping infection control dynamics. Hospitals significantly increased their investment in protective equipment, sterilization technologies, and disinfectants. This heightened awareness has continued beyond the pandemic, reinforcing a culture of infection prevention across healthcare facilities. The shift has resulted in lasting demand for disinfection solutions and digital monitoring tools. Consequently, the pandemic created a structural transformation, embedding infection control as a permanent priority within hospital operations.

Expanding public and private investments further strengthen the sector. Governments are allocating funds to upgrade hospital safety standards and support research into innovative infection control technologies. At the same time, private sector players are actively developing novel disinfectants, antimicrobial materials, and advanced sterilization equipment. These investments are driving faster product adoption and enhancing hospital preparedness worldwide. As the synergy between public health initiatives and private innovations increases, the hospital acquired infection control market is positioned for steady and resilient growth throughout the forecast period.

The Global Hospital Acquired Infection Control market size was valued at US$ 12.66 billion in 2022 and is predicted to be US$ 16.22 billion by 2030 with a CAGR of 3.2% during the forecast period. Hospital Acquired Infection Control Market Dynamics

Key Drivers of Hospital Acquired Infection Control Market

Growing Surgical Procedure 

The number of surgeries carried out worldwide has increased significantly. According to the National Institute of Health, 310 million major surgeries are performed each year. Due to an increasing elderly population, growing incidence of obesity and other lifestyle disorders, a surge in spinal injuries, and increased sport-related injuries. As a result, there is increasing demand for surgical equipment and devices. Due to the benefits of sterilized items, as well as the increasing knowledge of their efficacy in healthcare settings, this results in increasing demand for the hospital-acquired infection services market.

Growing Elderly Population 

Growing age causes the immune system to deteriorate. Older people are more frequently impacted by chronic illnesses like diabetes, hypertension, chronic obstructive pulmonary disease, and neurovascular diseases. Geriatric populations are more prone to hospital-acquired infection, therefore more focus on the prevention of the infection. As a result, it increases in demand for hospital-acquired infection services.

Key Restraint Factors for Hospital-Acquired Infection Control Market

Side Effects Associated with Disinfectant 

The majority of chemical disinfectants in the market nowadays have hazardous properties. Sodium hypochlorite, for example, is a potent disinfectant against blood-borne infections. It offers a risk to cleaning and disinfection employees since it is corrosive and an irritant to the respiratory system. Misused disinfectants pose a risk to the environment and patients who come into contact with them. Manufacturers are currently under pressure to develop cleaner, more environmentally friendly disinfectants that are less damaging to people's eyes, like pH-neutral quaternary, butyl-free, and disinfectants based on hydrogen peroxide.

Key Trends for Hospital Acquired Infection Control:

Growing Emerging Market:

The market for infection control is predicted to rise as a result of unexplored potential, enhanced infrastructure for the healthcare sector, an increase in the number of pharmaceutical and medical device companies, and increased consumer demand for infection control products. The healthcare sector is expanding in emerging economies as a result of the rise in demand for more sophisticated manufacturing systems and large government spending to update healthcare infrastructure.

Impact of the COVID-19 Pandemic on the Hospital-Acquired Infection Control Market:

The market for hospital-acquired infection management has been significantly impacted by the COVID-19 epidemic. Hospitals are getting overcrowded as a result of the pandemic's devastating effects on healthcare systems around the world. To handle the rising number of cases, temporary hospitals were also set up. The dissemination of COVID-19 has led to an increase in demand for HAI services as a result of the rising number of hospital-acquired infections in hospital settings. The severe COVID-19 effects, such as hospitalization, may, however, aid the hospital-acquired infection control business in gaining traction in the years to come in the wake of the pandemic. What is Hospital Acquired Infection Control?

Nosocomial-acquired illnesses that do not exist or incubate at the time of admission to a hospital are known as hospital-acquired infections. These infections include bloodstream infection linked to central lines, urinary tract infection linked to catheters, surgical site infection, pneumonia linked with ventilators, and infection with Clostridium difficile. These infections typically develop after being admitted to the hospital and become apparent 48 hours later. Organizations like the national healthcare safety network of disease control and prevention centers carefully monitor diseases. To stop the hospital-acquired infection and increase patient safety, surveillance is conducted. Increasing surgical procedures, a growing geriatric population, and increasing government initiatives drive market growth.

The Healthcare-Associated Infection (HAI) measures - provider data. These measures are developed by Centers for Disease Control and Prevention (CDC) and collected through the National Healthcare Safety Network (NHSN). They provide information on infections that occur while the patient is in the hospital. These infections can be related to devices, such as central lines and urinary catheters, or spread from patient to patient after contact with an infected person or surface. Many healthcare associated infections can be prevented when the hospitals use CDC-recommended infection control steps.

This statistic depicts the distribution of healthcare-associated infections (HAIs) in U.S. acute care hospitals in 2011, by causative pathogen. In that year, more than ** percent of all HAIs were due to the clostridium difficile organism.

The global market for Hospital-Acquired Infection (HAI) prevention and treatment products is experiencing robust growth, projected at a Compound Annual Growth Rate (CAGR) of 3.97% from 2025 to 2033, reaching an estimated market value exceeding $4.26 billion in 2025. This expansion is fueled by several key factors. Rising healthcare-associated infection rates globally, driven by increasing antibiotic resistance and aging populations requiring more complex medical procedures, present a significant challenge and fuel demand for effective sterilization and disinfection solutions. Technological advancements in sterilization equipment, such as the development of more efficient and environmentally friendly low-temperature sterilization technologies, are also contributing to market growth. The increasing prevalence of specific HAIs like hospital-acquired pneumonia, bloodstream infections, and surgical site infections are further propelling demand across various product segments, including sterilants (heat, low-temperature, radiation, and steam sterilization equipment), disinfectants, and other infection control products. Furthermore, stringent regulatory frameworks mandating infection control measures in healthcare facilities are boosting market adoption across different end-user segments, such as hospitals, ambulatory surgical centers, and nursing homes. The market is geographically diverse, with North America and Europe currently dominating, though regions like Asia-Pacific are witnessing rapid growth due to increasing healthcare infrastructure development and rising awareness of infection prevention. The competitive landscape is characterized by the presence of both large multinational corporations and specialized medical equipment manufacturers. Key players are strategically investing in research and development to enhance product efficacy, safety, and user-friendliness, further driving market growth. However, the market faces challenges such as high initial investment costs associated with advanced sterilization technologies and the potential for regulatory hurdles in various regions. Despite these challenges, the long-term outlook remains positive, driven by the continued need for effective HAI prevention and control strategies within healthcare settings globally. The market is segmented by product type (sterilants, disinfectants, and other products), indication (various types of HAIs), and end-user (hospitals, ambulatory surgical centers, etc.), providing opportunities for specialized product development and targeted market penetration. Recent developments include: In June 2022, Sonoma Pharmaceuticals, Inc. and the MicroSafe Group DMCC reported that Nanocyn hospital-grade disinfectant has been added to the list of COVID-19 disinfectants maintained by the United States Environmental Protection Agency's List N., In March 2022, PDI launched Sani-24 Germicidal Disposable Wipe, Sani-HyPerCide Germicidal Disposable Wipe, and Sani-HyPerCide Germicidal Spray, innovative disinfectants to help infection prevention professionals in the fight against rising healthcare-associated infections (HAIs) as well as the ongoing battle against COVID-19.. Key drivers for this market are: Increase in Hospital Stay Due to Chronic Diseases and Surgeries, Rise in the Incidences of Different Types of Hospital Acquired Infections; Innovative Technologies Implemented in Devices that Control Infection. Potential restraints include: Increase in Hospital Stay Due to Chronic Diseases and Surgeries, Rise in the Incidences of Different Types of Hospital Acquired Infections; Innovative Technologies Implemented in Devices that Control Infection. Notable trends are: Disinfectant Segment is Expected to Hold Significant Market Share Over the Forecast Period.

The global Hospital Acquired Infection (HAI) Control market size reached USD 29.13 Billion in 2021 and is expected to reach USD 33.49 Billion in 2030 registering a CAGR of 1.5%. Hospital Acquired Infection Control market growth is primarily driven owing to rising number of surgical procedures that r...

Hospital-acquired Infections Market Outlook

According to our latest research, the global hospital-acquired infections (HAI) market size reached USD 32.4 billion in 2024, reflecting a robust demand for infection control measures and related products worldwide. The market is expected to grow at a CAGR of 7.8% during the forecast period, reaching an estimated USD 63.7 billion by 2033. This growth is primarily driven by the rising prevalence of HAIs, increasing healthcare expenditures, and the growing implementation of stringent infection control policies across healthcare facilities globally. As per the latest research, the market's expansion is further supported by technological advancements in diagnostic techniques and sterilization equipment, coupled with heightened awareness regarding patient safety and infection prevention.

One of the significant growth factors for the hospital-acquired infections market is the escalating incidence of HAIs, particularly in developing healthcare systems where infection control measures are still evolving. The World Health Organization estimates that hundreds of millions of patients are affected by HAIs every year, leading to prolonged hospital stays, increased antimicrobial resistance, and substantial financial burdens for healthcare systems. The growing geriatric population and the rising number of surgical procedures globally further contribute to the vulnerability of patients to HAIs. Additionally, the increasing use of invasive medical devices, such as catheters and ventilators, has amplified the risk of infections, thereby propelling the demand for advanced sterilization and disinfection solutions.

Another critical driver is the heightened focus on patient safety and regulatory compliance. Governments and healthcare organizations worldwide are implementing stringent guidelines and protocols to minimize the incidence of HAIs. Regulatory bodies such as the Centers for Disease Control and Prevention (CDC) and the European Centre for Disease Prevention and Control (ECDC) have introduced comprehensive surveillance programs and infection prevention strategies. These initiatives are prompting healthcare facilities to invest in state-of-the-art sterilization equipment, high-efficacy disinfectants, and rapid diagnostic tools. Furthermore, the integration of digital technologies, such as electronic health records and real-time monitoring systems, is enabling better tracking and management of infection outbreaks, thus fostering market growth.

Technological advancements in diagnostic and treatment modalities are also playing a pivotal role in the expansion of the hospital-acquired infections market. The development of rapid and accurate diagnostic techniques has significantly improved the early detection and management of HAIs, reducing morbidity and mortality rates. Innovations in sterilization technologies, such as low-temperature hydrogen peroxide plasma sterilizers and ultraviolet (UV) disinfection systems, are enhancing the efficacy of infection control in healthcare settings. Moreover, the growing pipeline of novel antimicrobial agents and the increasing adoption of antimicrobial stewardship programs are contributing to the effective management and treatment of HAIs, thereby supporting the overall market growth.

From a regional perspective, North America continues to dominate the hospital-acquired infections market, accounting for the largest revenue share in 2024. This dominance can be attributed to the presence of advanced healthcare infrastructure, high healthcare spending, and a strong regulatory framework. However, the Asia Pacific region is witnessing the fastest growth, driven by rising healthcare investments, increasing awareness about infection control, and the rapid expansion of healthcare facilities in emerging economies such as China and India. Europe also holds a significant share of the market, supported by robust government initiatives and a well-established healthcare system. Latin America and the Middle East & Africa are gradually catching up, fueled by improvements in healthcare delivery and growing efforts to combat HAIs.

Infection Type Analysis

The hospital-acquired infections market is segmented by infection type into urinary tract infections (UTIs), surgical site infections (SSIs), bloodstream infections (BSIs), pneumonia, gastrointestinal infections, and others. Among these, urinary tract infections represent the most common type of HAI, accounting for a subst

From USD 7,441.8 Million in 2025, The market is anticipated to grow to USD 14,368 Million, recording a 6.8% CAGR in the forecasted period 2025 to 2035. The key factors driving the growth of the market are increasing number of surgical procedures, rising geriatric population and growth in the adoption of advanced sterilization and disinfection product.

Country-Wise Outlook

Competitive Outlook

Hospital-Acquired Infection Risk AI Market Outlook

According to our latest research, the global Hospital-Acquired Infection Risk AI market size reached USD 1.42 billion in 2024, underscoring rapid adoption of artificial intelligence in healthcare settings. The market is projected to grow at a robust CAGR of 18.7% from 2025 to 2033, with the forecasted market value expected to hit USD 7.32 billion by 2033. This remarkable growth is primarily driven by the urgent need to reduce the prevalence of hospital-acquired infections (HAIs) and the increasing integration of AI-powered risk assessment and surveillance tools within healthcare facilities worldwide.

The primary growth factor for the Hospital-Acquired Infection Risk AI market is the global upsurge in awareness regarding HAIs and their significant impact on patient safety and healthcare costs. Hospital-acquired infections continue to affect millions of patients annually, leading to extended hospital stays, increased morbidity, and substantial financial burdens on healthcare systems. As healthcare providers and regulatory bodies intensify efforts to curb infection rates, AI-driven solutions have emerged as essential tools for real-time surveillance, risk prediction, and clinical decision support. These solutions enable earlier detection of infection risks, facilitate timely interventions, and support evidence-based infection control policies, thereby driving widespread adoption of AI technologies in infection prevention.

Another key driver propelling the Hospital-Acquired Infection Risk AI market is the rapid advancement in machine learning algorithms, natural language processing, and big data analytics. These technological innovations have significantly enhanced the accuracy and efficiency of AI platforms in identifying infection patterns, predicting outbreaks, and providing actionable insights to clinicians and infection control teams. The integration of AI with electronic health records (EHRs), laboratory information systems, and hospital management platforms has further streamlined data collection and analysis, enabling seamless workflow integration and improved clinical outcomes. As hospitals and clinics increasingly recognize the value of AI in optimizing infection prevention strategies, demand for advanced AI-based risk assessment and surveillance solutions is expected to soar in the coming years.

The growing trend toward digital transformation in healthcare is also contributing to the expansion of the Hospital-Acquired Infection Risk AI market. Governments and healthcare organizations across the globe are investing heavily in digital health infrastructure, including cloud-based platforms and interoperable health information systems. These investments are facilitating the deployment of scalable, AI-powered infection risk management solutions that can be accessed remotely and integrated with existing hospital IT ecosystems. The COVID-19 pandemic has further accelerated this digital shift, highlighting the critical need for intelligent infection control tools capable of supporting proactive, data-driven decision-making in high-pressure environments.

From a regional perspective, North America currently leads the Hospital-Acquired Infection Risk AI market, accounting for the largest share in 2024, followed closely by Europe and Asia Pacific. The dominance of North America is attributed to the presence of a well-established healthcare infrastructure, high adoption rates of advanced technologies, and stringent regulatory mandates related to infection prevention and patient safety. Meanwhile, Asia Pacific is expected to exhibit the highest growth rate over the forecast period, driven by increasing healthcare investments, rising incidence of HAIs, and growing awareness about the benefits of AI-driven infection risk management solutions. Europe remains a key market, with strong emphasis on healthcare quality, digital health initiatives, and collaborative research activities fueling market growth.

Component Analysis

The Compon

Hospital-acquired infections (HAI) are often seen as preventable incidents that result from unsafe practices or poor hospital hygiene. This however ignores the fact that transmissibility is not only a property of the causative organisms but also of the hosts who can translocate bacteria when moving between hospitals. In an epidemiological sense, hospitals become connected through the patients they share. We here postulate that the degree of hospital connectedness crucially influences the rates of infections caused by hospital-acquired bacteria. To test this hypothesis, we mapped the movement of patients based on the UK-NHS Hospital Episode Statistics and observed that the proportion of patients admitted to a hospital after a recent episode in another hospital correlates with the hospital-specific incidence rate of MRSA bacteraemia as recorded by mandatory reporting. We observed a positive correlation between hospital connectedness and MRSA bacteraemia incidence rate that is significant for all financial years since 2001 except for 2008–09. All years combined, this correlation is positive and significantly different from zero (partial correlation coefficient r = 0.33 (0.28 to 0.38)). When comparing the referral pattern for English hospitals with referral patterns observed in the Netherlands, we predict that English hospitals more likely see a swifter and more sustained spread of HAIs. Our results indicate that hospitals cannot be viewed as individual units but rather should be viewed as connected elements of larger modular networks. Our findings stress the importance of cooperative effects that will have a bearing on the planning of health care systems, patient management and hospital infection control.

Hospital Acquired Infections Control Market Outlook

The global hospital-acquired infections control market size was valued at approximately USD XX billion in 2023, and is anticipated to reach USD XX billion by 2032, growing at a compound annual growth rate (CAGR) of XX% during the forecast period. The market is experiencing a robust expansion, primarily driven by the increasing prevalence of hospital-acquired infections (HAIs) and heightened awareness regarding infection prevention and control measures. As healthcare systems globally grapple with the challenges posed by HAIs, there is a growing emphasis on enhancing infection control protocols, driving the demand for effective control products and solutions.

One of the key growth factors fueling the market is the rising incidence of HAIs across healthcare facilities worldwide. HAIs pose a significant challenge to patient safety, leading to prolonged hospital stays, increased morbidity and mortality rates, and higher healthcare costs. The Centers for Disease Control and Prevention (CDC) estimates that approximately one in 31 hospital patients has at least one healthcare-associated infection on any given day. Such alarming statistics underscore the urgent need for robust infection control measures, which in turn propels the demand for advanced disinfection and sterilization products and services.

Moreover, stringent regulatory guidelines and standards set by healthcare authorities are playing a pivotal role in driving the market growth. Regulatory bodies such as the World Health Organization (WHO), CDC, and others have recommended specific protocols and procedures to minimize the risk of HAIs. Compliance with these standards is imperative for healthcare facilities, prompting them to invest in effective infection control measures. Additionally, the increasing adoption of surveillance systems for early detection and management of infections is further augmenting market growth, as healthcare providers seek to ensure adherence to regulatory requirements and enhance patient outcomes.

Technological advancements in infection control products and solutions are significantly contributing to market expansion. Innovations in disinfection technologies, such as UV-C disinfection systems and antimicrobial coatings, are gaining traction due to their efficacy in reducing microbial load in healthcare settings. Similarly, advancements in sterilization equipment, including the development of low-temperature sterilization technologies, are enhancing the efficiency and safety of sterilization processes. These technological innovations are anticipated to drive the adoption of advanced infection control solutions, bolstering market growth in the coming years.

Regionally, North America is expected to dominate the hospital-acquired infections control market, attributed to the well-established healthcare infrastructure, high awareness levels, and stringent regulations regarding infection prevention and control. Europe is also anticipated to witness substantial growth, driven by increasing healthcare expenditures and initiatives aimed at reducing HAIs. The Asia Pacific region is projected to register the highest CAGR during the forecast period, owing to the rising healthcare investments, growing awareness, and increasing incidence of HAIs in emerging economies such as China and India.

Hospital-Acquired Pneumonia Prevention has become a focal point in the broader strategy to combat HAIs. Pneumonia acquired in hospital settings, particularly among patients on ventilators, poses a significant risk due to its association with increased morbidity and mortality. Effective prevention strategies include the implementation of comprehensive oral care protocols, the use of closed suction systems, and adherence to hand hygiene practices. These measures are crucial in reducing the incidence of ventilator-associated pneumonia (VAP), a common and severe form of hospital-acquired pneumonia. By focusing on these preventive strategies, healthcare facilities can significantly enhance patient safety and improve clinical outcomes, ultimately reducing the burden of HAIs.

Product Type Analysis

The hospital-acquired infections control market is segmented by product type into disinfectants, sterilization equipment, protective barriers, surveillance systems, and others. Disinfectants, which include solutions, wipes, and sprays, remain a critical component in infection control protocols. The growing emphasis on maintaining hyg

In FY2022, from the 3,124 hospitals Medicare assessed, 764 were penalized for high rates of hospital-acquired conditions (HAC). This is lower than the highest number to date of 800 hospitals recorded in 2019.

The hospital-acquired conditions reduction program (HACRP) was created as part of Affordable Care Act's (ACA's) payment and delivery system reform, to focus on quality rather than quantity of care. Hospitals are ranked by the rates of HACs such as infections, bed sores and post-operative blood clots. The Centers for Medicare & Medicaid Services penalizes the lowest performing 25 percent of all hospitals each year one percent of their Medicare hospital payments. Critics have voiced that the program will always punish the lowest performing quartile regardless if they made any improvement from the previous year and that teaching hospitals, where infections are more rigorously tested for, are more often punished by the program. This statistic presents the number of hospitals in the United States that Medicare punished for high rates of hospital-acquired conditions from FY2015 to FY2022.

This statistic depicts the distribution of of patients with healthcare-associated infections (HAIs) in U.S. acute care hospitals in 2011. It was estimated that around ** percent of all these patients had surgical site infections (SSIs).

The Infection Surveillance Solutions market, valued at $0.63 billion in 2025, is poised for robust growth, exhibiting a Compound Annual Growth Rate (CAGR) of 13.87% from 2025 to 2033. This expansion is fueled by several key factors. Increasing healthcare-associated infections (HAIs) globally necessitate advanced surveillance systems to mitigate risks and improve patient safety. The rising adoption of electronic health records (EHRs) and the integration of advanced analytics within infection control programs streamline data collection and analysis, leading to more effective interventions. Furthermore, stringent regulatory compliance mandates and increasing emphasis on infection prevention and control initiatives within healthcare facilities are driving market growth. The market is segmented by offering (Software – On-Premise and Cloud; Services – Maintenance & Support, Consultation & Training, Implementation Services) and end-user (Hospitals, Long-Term Care Facilities, and Other End Users). Hospitals currently dominate the market due to their higher infection risk profiles and greater resources allocated to infection control. However, the long-term care facilities segment is expected to witness significant growth due to the increasing aging population and vulnerability to HAIs within these settings. Key players such as Becton Dickinson, Gojo Industries, Epic Systems, and IBM are actively shaping market dynamics through technological innovations and strategic partnerships. North America currently holds a significant market share, driven by advanced healthcare infrastructure and increased adoption of sophisticated infection surveillance solutions. However, Asia-Pacific is projected to experience rapid growth due to rising healthcare expenditure, increasing awareness of infection control, and expanding healthcare infrastructure. While the market faces restraints such as high implementation costs and the need for skilled professionals to operate sophisticated systems, the overall market outlook remains positive, driven by the undeniable need for robust infection surveillance strategies to minimize HAIs and ensure improved patient outcomes. The ongoing development of artificial intelligence (AI) and machine learning (ML) based solutions further promises to enhance the accuracy and efficiency of infection surveillance, paving the way for accelerated market growth in the coming years. This comprehensive report provides an in-depth analysis of the Infection Surveillance Solutions industry, encompassing market size, trends, growth drivers, and competitive landscape. The study period covers 2019-2033, with 2025 as the base and estimated year, and a forecast period of 2025-2033. This detailed analysis is crucial for stakeholders seeking to understand and capitalize on the growing demand for infection prevention and control solutions across healthcare settings. The report offers insights into key players, market segmentation, and future growth potential, empowering informed decision-making. This report utilizes high-search-volume keywords, such as infection surveillance, healthcare software, hospital infection control, long-term care technology, cloud-based infection surveillance, and AI in healthcare to maximize search engine visibility. Recent developments include: September 2022: GSK plc and Microsoft, in an innovative partnership with the Centre for Health and Disease Studies (CHDS) Nepal, initiated a groundbreaking disease surveillance project in Nepal. This pilot program harnesses the advanced capabilities of Microsoft's Premonition systems and combines them with GSK's extensive knowledge in health and disease management. The primary goal of this endeavor is to explore the potential of artificial intelligence and robotics in bolstering the local community's ability to combat vector-borne diseases and address the challenges posed by climate change., June 2022: Premier introduced the PINC AI solution tailored for long-term care (LTC) facilities. This cutting-edge solution offers the same level of clinical surveillance found in acute care settings, representing a significant advancement in the realm of long-term care technology.. Key drivers for this market are: Stringent Government Policies for Preventing Hospital Associated Infections, Rise in the Number of Surgeries. Potential restraints include: Reluctance Among Medical Professionals to Adopt Advanced Healthcare Tools. Notable trends are: Infection Surveillance by Services is expected to Drive the Market Growth.

Hospital-Acquired Infection Testing Market Outlook

According to our latest research, the global hospital-acquired infection (HAI) testing market size in 2024 stands at USD 5.1 billion, reflecting the increasing prioritization of infection control in healthcare settings. The market is experiencing robust expansion, with a CAGR of 7.2% projected from 2025 to 2033. By the end of 2033, the hospital-acquired infection testing market is expected to reach USD 9.6 billion. This growth is primarily driven by the rising incidence of HAIs worldwide, advancements in diagnostic technologies, and stringent regulatory requirements for infection control in hospitals and healthcare facilities.

One of the most significant growth factors for the hospital-acquired infection testing market is the mounting global burden of HAIs, which are a major cause of morbidity and mortality in clinical settings. The increasing awareness among healthcare professionals and administrators regarding the severe consequences of untreated or late-diagnosed infections has led to a surge in demand for rapid and accurate diagnostic solutions. Additionally, the growing prevalence of multidrug-resistant organisms in hospitals has necessitated the adoption of advanced testing technologies, further propelling market growth. Enhanced surveillance programs and infection prevention protocols mandated by health authorities and accreditation bodies are also contributing to the rising adoption of HAI testing products and services.

Technological advancements have played a pivotal role in shaping the hospital-acquired infection testing market. The integration of cutting-edge molecular diagnostics, such as PCR and next-generation sequencing, has significantly improved the speed, sensitivity, and specificity of infection detection. These innovations enable healthcare providers to identify pathogens more accurately and initiate timely treatment, thus reducing the risk of outbreaks and improving patient outcomes. Furthermore, the development of user-friendly point-of-care testing devices and automated systems has streamlined workflow in clinical laboratories, minimizing manual errors and enhancing operational efficiency. The continuous evolution of diagnostic platforms is expected to drive further adoption and fuel market expansion over the forecast period.

Another key driver of market growth is the increasing investment by governments and private organizations in healthcare infrastructure and infection control initiatives. Many countries have implemented strict regulations and guidelines for infection surveillance, testing, and reporting, compelling healthcare facilities to upgrade their diagnostic capabilities. The presence of favorable reimbursement policies for HAI testing in developed regions has further incentivized hospitals and laboratories to adopt advanced testing solutions. In addition, the COVID-19 pandemic has heightened the focus on infection prevention and control, leading to increased funding and resource allocation for HAI management. These factors collectively create a conducive environment for sustained growth in the hospital-acquired infection testing market.

From a regional perspective, North America continues to dominate the hospital-acquired infection testing market, driven by a well-established healthcare infrastructure, high awareness levels, and strong regulatory oversight. Europe follows closely, with significant investments in healthcare quality improvement and infection surveillance programs. The Asia Pacific region is witnessing the fastest growth, attributed to rising healthcare expenditure, expanding hospital networks, and increasing government initiatives to combat HAIs. Latin America and the Middle East & Africa are also experiencing steady growth, supported by improving healthcare systems and growing adoption of advanced diagnostic technologies. Regional disparities in market size and growth rates are influenced by differences in healthcare infrastructure, regulatory frameworks, and disease prevalence.

Product Type Analysis

The hospital-acquired infection testing market by product type is segmented into instruments, consumables, and software. Instruments represent a substantial share of the market, as they form the backbone of diagnostic workflows in hospitals and laboratories. These include automated analyzers, PCR machines, immunoassay platforms, and microbiology systems, all of which are essential for accurate and timely de

Hospital Acquired Disease Testing Market Outlook

According to our latest research, the global Hospital Acquired Disease Testing market size in 2024 stands at USD 4.9 billion, with a robust trajectory driven by heightened awareness and stringent infection control protocols. The market is expected to register a CAGR of 7.2% from 2025 to 2033, reaching a projected value of USD 9.2 billion by the end of the forecast period. This growth is primarily attributed to the increasing incidence of hospital-acquired infections (HAIs), rapid technological advancements in diagnostic tools, and the rising emphasis on early disease detection for improved patient outcomes. As per our latest research, the demand for efficient, rapid, and reliable testing solutions continues to surge globally, reflecting the critical need for enhanced infection surveillance and control within healthcare facilities.

One of the most significant growth factors in the Hospital Acquired Disease Testing market is the escalating prevalence of HAIs across healthcare settings. The World Health Organization (WHO) estimates that hundreds of millions of patients are affected by HAIs each year, leading to prolonged hospital stays, increased antimicrobial resistance, and higher mortality rates. This alarming scenario has compelled healthcare institutions to prioritize infection control strategies, which in turn, is fueling the demand for advanced diagnostic solutions. The adoption of rapid and accurate testing methods not only aids in timely intervention but also helps in curbing the spread of infections, thereby improving overall patient safety. Furthermore, regulatory bodies worldwide are mandating stricter compliance with infection prevention protocols, thereby fostering a favorable environment for market expansion.

Technological advancements in diagnostic methodologies are another key driver propelling the Hospital Acquired Disease Testing market. The integration of molecular diagnostics, next-generation sequencing, and automated immunoassays has revolutionized the detection of pathogens responsible for HAIs. These innovations offer higher sensitivity, specificity, and faster turnaround times compared to conventional testing methods. The increasing adoption of point-of-care (POC) testing devices and digital health platforms further enhances the efficiency of disease surveillance and reporting. Additionally, ongoing research and development activities are leading to the introduction of novel biomarkers and multiplex assays, which enable simultaneous detection of multiple pathogens, thereby streamlining the diagnostic workflow and reducing operational costs for healthcare providers.

The growing burden of antibiotic-resistant infections is also significantly influencing the Hospital Acquired Disease Testing market. Multidrug-resistant organisms such as MRSA, VRE, and CRE pose substantial challenges to effective treatment and infection control. The rise in antimicrobial resistance has necessitated the implementation of robust infection surveillance programs and the use of advanced diagnostic tools capable of detecting resistant strains. Hospitals and diagnostic laboratories are increasingly investing in state-of-the-art testing platforms that can provide actionable insights for targeted therapy. This trend is further supported by government initiatives aimed at combating antimicrobial resistance through improved diagnostics and stewardship programs, thereby accelerating market growth.

From a regional perspective, North America currently dominates the Hospital Acquired Disease Testing market, accounting for the largest share in 2024, followed closely by Europe. The Asia Pacific region, however, is poised to experience the fastest growth rate during the forecast period, driven by rising healthcare expenditures, expanding hospital infrastructure, and increasing awareness regarding infection control. Latin America and the Middle East & Africa are also witnessing steady growth, supported by government-led initiatives to strengthen healthcare systems and enhance diagnostic capabilities. The global landscape is characterized by a growing emphasis on cross-border collaborations, knowledge sharing, and capacity building to address the challenges posed by HAIs, further contributing to the overall market expansion.

Hospital-acquired infections (HAIs), including emerging multi-drug resistant organisms, threaten healthcare systems worldwide. Efficient containment measures of HAIs must mobilize the entire healthcare network. Thus, to best understand how to reduce the potential scale of HAI epidemic spread, we explore patient transfer patterns in the French healthcare system. Using an exhaustive database of all hospital discharge summaries in France in 2014, we construct and analyze three patient networks based on the following: transfers of patients with HAI (HAI-specific network); patients with suspected HAI (suspected-HAI network); and all patients (general network). All three networks have heterogeneous patient flow and demonstrate small-world and scale-free characteristics. Patient populations that comprise these networks are also heterogeneous in their movement patterns. Ranking of hospitals by centrality measures and comparing community clustering using community detection algorithms shows that despite the differences in patient population, the HAI-specific and suspected-HAI networks rely on the same underlying structure as that of the general network. As a result, the general network may be more reliable in studying potential spread of HAIs. Finally, we identify transfer patterns at both the French regional and departmental (county) levels that are important in the identification of key hospital centers, patient flow trajectories, and regional clusters that may serve as a basis for novel wide-scale infection control strategies.